Addex Therapeutics Ltd.
corporate_fare Company Profile
Addex Therapeutics Ltd. (NASDAQ:ADXN) is a publicly traded company in the Life Sciences sector. Wiseek monitors ADXN SEC EDGAR filings and licensed market news in real time, scoring each submission for market-moving significance on a 1–10 scale. Items rated 7 or higher generate instant alerts.
Recent high-impact activity:
- Shareholders Approve Capital Band Increase, Enabling Future Financing for Distressed Addex Therapeutics
- Addex Therapeutics Reports Increased Q1 Loss, Critically Low Cash, and Going Concern Warning
- Addex Therapeutics' Cash Dips Below CHF 1M Amid Widening Q1 Loss, Intensifying Going Concern Risk
- Addex Therapeutics Seeks Shareholder Approval to Increase Capital for Future Funding
- Addex Therapeutics Reports Critical Going Concern Warning, Low Cash, and Material Internal Control Weakness in Annual Report
Financial Snapshot
Dilution Risk
Low riskFiling-implied dilution signals for ADXN, detected from its recent SEC filings · based on capital-structure filings through 2026-06-05.
AGM Convened · Capital Increase Proposal
⚠ A more recent filing has been published for this ticker since this signal was computed; it may not yet be reflected — see the filings below.
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →
Insider Transactions
ADXN files as a Foreign Private Issuer (FPI). Under SEC Exchange Act Section 16(a), officers, directors, and 10% owners of FPIs are exempt from Form 4 insider-transaction reporting requirements. Comparable disclosures, when applicable, appear in the company's Form 20-F (annual) or Form 6-K (interim) filings on SEC EDGAR.